Shire plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Kim Stratton, was filed 08 Jan 2019.
Shire plc: what insiders have been doing
This page follows insider dealings at Shire plc as filed with RNS (LSE). The past year has been quiet: not a single insider filing for Shire plc. The previous disclosure was published on 8 January 2019.
The full history, which starts in 2017, counts 33 purchases against 15 sales.
Elsewhere in the same market, our signals recently picked up insider purchases at CMC Markets plc. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
- 45,601 shares@ £0.9504100.0% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-0Canonical exit: 8 Apr 2019 (T+90)
- 6,147 shares@ £1.5495100.0% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-4Canonical exit: 8 Apr 2019 (T+90)
- 1,485 shares@ £1.68542.4% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-5
- 5,162 shares@ £0.0578100.0% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-7
- 772 shares@ £1.68542.6% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-3
- 7,628 sharesN/AISIN JE00B2QKY057FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-2Canonical exit: 8 Apr 2019 (T+90)
- 9,787 shares@ £0.243.5% of flowN/AISIN JE00B2QKY057FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-6Canonical exit: 8 Apr 2019 (T+90)
- 2,544 sharesN/AISIN JE00B2QKY057FCA-NSM:NASDAQ_1000143349-en_20200326185116545_23786-1Canonical exit: 8 Apr 2019 (T+90)
- 164 shares@ £1.68051.1% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-0Canonical exit: 20 Mar 2019 (T+90)
- 140 shares@ £0.44310.8% of flowLSE (TRQX)ISIN JE00B2QKY057FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-1Canonical exit: 20 Mar 2019 (T+90)
- 44 shares@ £1.68050.8% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-2Canonical exit: 20 Mar 2019 (T+90)
- 47 shares@ £1.68040.7% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-3Canonical exit: 20 Mar 2019 (T+90)
- 44 shares@ £1.68050.8% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-5Canonical exit: 20 Mar 2019 (T+90)
- 46 shares@ £1.68040.8% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-6Canonical exit: 20 Mar 2019 (T+90)
- 63 shares@ £1.68050.9% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-7Canonical exit: 20 Mar 2019 (T+90)
- 49 shares@ £1.68040.9% of flowXNAS / XBOS / ARCXISIN US82481R1068FCA-NSM:NASDAQ_1000141317-en_20200330111409206_19871-4Canonical exit: 20 Mar 2019 (T+90)
- 12,050 sharesNASDAQISIN US82481R1068FCA-NSM:NASDAQ_1000140442-en_20200330111408457_14033-1
- 8,853 sharesNASDAQISIN US82481R1068FCA-NSM:NASDAQ_1000140442-en_20200330111408457_14033-0
- 1,011 sharesNASDAQISIN US82481R1068FCA-NSM:NASDAQ_1000140442-en_20200330111408457_14033-2
- 12,665 sharesNASDAQISIN US82481R1068FCA-NSM:NASDAQ_1000140442-en_20200330111408457_14033-3
- 99 shares@ £1.25490.0% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000104889-en_20200330111439173_29514-0
- 99 shares@ £1.25490.2% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000104889-en_20200330111439173_29514-1
- 99 shares@ £1.25490.0% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000104889-en_20200330111439173_29514-2
- 99 shares@ £1.25490.1% of flowN/AISIN US82481R1068FCA-NSM:NASDAQ_1000104889-en_20200330111439173_29514-3
- 297 shares@ £0.31630.1% of flowLondon Stock Exchange (XLON)ISIN JE00B2QKY057FCA-NSM:NASDAQ_1000104889-en_20200330111439173_29514-4
25 of 81 declarations
About Shire plc
Shire plc is a biopharmaceutical company focused on developing treatments for rare and complex diseases. It was acquired by Takeda Pharmaceutical Company in 2019.
